Loading
Loading
Research Overview
Recombinant human growth hormone; activates GHR/JAK2/STAT5 signalling cascade to promote IGF-1 production, protein synthesis, lipolysis, and cell proliferation across multiple tissue types.
Overview
Recombinant human growth hormone is a single-chain polypeptide produced by somatotroph cells of the anterior pituitary gland and widely used in laboratory research as a reference standard and pharmacological tool for studying GH biology. Preclinical research has employed rhGH to characterise growth hormone receptor signalling through the JAK2-STAT5 pathway, downstream IGF-1 production in liver and peripheral tissues, and the tissue-specific anabolic and metabolic consequences of GH receptor activation.
In preclinical metabolic research, growth hormone has been studied for its complex role in regulating lipolysis, protein synthesis, and carbohydrate metabolism in animal models. Laboratory investigations have characterised how GH promotes fatty acid mobilisation from adipose tissue while stimulating protein anabolism in skeletal muscle, and how these effects interact with insulin signalling in models of metabolic regulation.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, human growth hormone (hgh / somatropin) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Recombinant human growth hormone; activates GHR/JAK2/STAT5 signalling cascade to promote IGF-1 production, protein synthesis, lipolysis, and cell proliferation across multiple tissue types.
Support
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.